Olema director granted 29,500 stock options

Olema Pharmaceuticals director Garland J. Scott received a grant of stock options covering 29,500 shares of common stock.

Rhea-AI Filing Summary

Olema Pharmaceuticals director Garland J. Scott received a grant of stock options covering 29,500 shares of common stock. The options have an exercise price of $9.51 per share and expire on June 18, 2036. Following this grant, Scott holds options for 29,500 shares directly.

The options vest in 12 equal monthly installments starting on June 18, 2026, subject to continuous service. Any unvested portion will vest in full on the date of Olema’s next annual stockholder meeting if the option is not already fully vested by then.

Insider Trade Summary

Grant/Award: 29,500 shares

Grant/Award 1 txn

Insider Garland J. Scott

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	29,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 29,500 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

Key Figures

Options granted: 29,500 shares Exercise price: $9.51 per share Shares underlying options: 29,500 shares +3 more

6 metrics

Options granted 29,500 shares Stock Option (right to buy) grant to director

Exercise price $9.51 per share Strike price for stock option grant

Shares underlying options 29,500 shares Common Stock underlying derivative security

Expiration date June 18, 2036 Option expiration for this grant

Post-grant derivative holdings 29,500 options Total shares following transaction (derivative)

Monthly vesting schedule 12 installments Equal monthly vesting starting June 18, 2026

Key Terms

Stock Option (right to buy), exercise price, vest in a series of 12 successive equal monthly installments, expiration date, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 9.5100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in a series of 12 successive equal monthly installments financial

"The shares subject to the option vest in a series of 12 successive equal monthly installments"

expiration date financial

"expiration_date: 2036-06-18T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

annual meeting of stockholders financial

"Such shares vest in full on the date of the Issuer's next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Garland J. Scott receive in this Olema (OLMA) Form 4 filing?

Garland J. Scott received a grant of stock options for 29,500 shares. These options give him the right to buy Olema common stock at a fixed price, serving as equity-based compensation tied to his continued service as a director.

What is the exercise price of Garland J. Scott’s Olema (OLMA) stock options?

The stock options have an exercise price of $9.51 per share. This means Scott can buy Olema common stock at $9.51 regardless of the market price when he eventually exercises the vested portion of the options.

How do Garland J. Scott’s Olema (OLMA) stock options vest over time?

The 29,500 options vest in 12 equal monthly installments starting June 18, 2026. Vesting requires Scott’s continuous service through each vesting date, gradually increasing the number of options he is allowed to exercise.

When do Garland J. Scott’s Olema (OLMA) options fully vest at the latest?

Any unvested options vest in full on Olema’s next annual stockholder meeting date. This accelerated vesting occurs only if the option is not otherwise fully vested and Scott continues serving through that meeting date.

When do Garland J. Scott’s Olema (OLMA) stock options expire?

The options expire on June 18, 2036. After that expiration date, any unexercised options will lapse, and Scott will no longer have the right to purchase Olema shares under this specific grant.

How many Olema (OLMA) option shares does Garland J. Scott hold after this grant?

After this grant, Scott holds options for 29,500 shares of Olema common stock. This entire option position comes from the new grant reported, with no additional derivative positions shown in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 05:28 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Garland J. Scott

(Last) (First) (Middle)

C/O OLEMA PHARMACEUTICALS, INC.

780 BRANNAN ST

(Street)

SAN FRANCISCO CALIFORNIA 94103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Olema Pharmaceuticals, Inc. [ OLMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$9.51	06/18/2026		A		29,500		(1)	06/18/2036	Common Stock	29,500	$0	29,500	D

Explanation of Responses:

1. The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Shawnte Mitchell, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)